查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1636752

膀胱癌治疗和诊断市场预测至 2030 年：按癌症类型、治疗、诊断、治疗阶段、最终用户和地区进行的全球分析

Bladder Cancer Therapeutics and Diagnostics Market Forecasts to 2030 - Global Analysis by Cancer Type, Therapeutics, Diagnostics, Treatment Stage, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球膀胱癌治疗和诊断市场预计在 2024 年达到 4.715 亿美元，到 2030 年将达到 7.864 亿美元，预测期内的复合年增长率为 8.9%。

膀胱癌治疗和诊断是用于管理和识别膀胱癌的医疗治疗和技术。治疗可能包括多种治疗方法，包括手术、化疗、免疫疗法、放射线治疗和标靶治疗，所有这些治疗方法都是为了杀死癌细胞或阻止其生长。诊断包括多种测试和程序，例如尿液检查、膀胱镜检查、影像（例如电脑断层扫描、超音波）和切片检查，以检测和分期癌症。早期发现和先进治疗对于提高存活率至关重要，个人化医疗的持续研究正在提高治疗和诊断方法的有效性。

根据美国癌症协会统计，预计 2022 年美国将出现约 81,180 例膀胱癌新病例。

膀胱癌发生率上升

膀胱癌发生率的上升正在推动膀胱癌治疗和诊断市场的发展。随着越来越多的人被诊断出患有癌症，对先进诊断工具（如影像和生物标记测试）以及创新治疗方案（如标靶治疗、免疫疗法和化疗）的需求也日益增长。对早期发现和个人化治疗的日益增长的需求推动了市场的成长，医疗保健提供者和製药公司专注于开发新的治疗方法和诊断解决方案，以应对膀胱癌日益增长的盛行率。

医疗费用高昂

膀胱癌的治疗和诊断费用昂贵，这成为市场扩张的一大障碍，尤其是在中低收入国家。免疫疗法和标靶治疗等现代药物价格昂贵，限制了患者的治疗机会和负担能力。保险覆盖范围和自付费用的差异加剧了这个问题，阻碍了快速诊断和有效治疗，延迟了患者的治疗效果并阻碍了更广泛的市场应用。

早期检测技术

早期检测技术可实现早期诊断、改善治疗效果并降低死亡率，对膀胱癌治疗和诊断市场产生重大影响。液态切片等技术、诊断成像的进步以及生物标记测试使得人们能够在早期阶段识别癌症，从而製定个性化的治疗方案。这将提高治疗效率，最大限度地减少副作用并降低医疗成本。因此，在这些技术创新的推动下，膀胱癌诊断和治疗市场正在迅速扩大。

治疗的副作用

化疗、免疫疗法和放射线治疗等膀胱癌治疗的副作用会降低患者的依从性和治疗效果，从而阻碍市场的成长。疲劳、噁心和免疫相关问题是一些可能降低生活品质并导致治疗中断或延迟的副作用。这将引起患者和医疗保健专业人士的担忧，减缓某些治疗方法的采用，并阻碍整个膀胱癌治疗和诊断市场的成长。

COVID-19 的影响：

COVID-19 疫情导致选择性手术延迟、患者就诊减少、临床试验受限，扰乱了膀胱癌治疗和诊断市场。诊断测试和治疗的可用性受到影响，导致护理延迟。然而，疫情后对癌症治疗的关注度增加以及远端医疗和远距离诊断的加速应用将支持市场復苏，从而长期推动对创新治疗方法和诊断解决方案的需求。

膀胱镜检查细分市场预计将在预测期内成长至最大

膀胱镜检查预计将在预测期内占据最大的份额，因为它可以直接观察膀胱内壁，有助于识别肿瘤和异常。此诊断工具可支援切片检查程序并有助于更精确的治疗计划。随着全球膀胱癌发病率的不断上升，膀胱镜检查在早期诊断和后续治疗性介入中的作用正在推动诊断和治疗领域的成长。

预计预测期内放射肿瘤学领域将以最高的复合年增长率成长。

放射治疗领域预计在预测期内将以最高的复合年增长率成长，因为它通常与手术和化疗结合以提高存活率。放射治疗技术的进步，例如影像导航放射治疗(IGRT) 和强度调控放射治疗(IMRT)，提高了精确度并减少了副作用。这些技术创新以及对监测治疗效果和检测復发的先进诊断工具的日益增长的需求正在推动市场的发展。

占比最大的地区：

由于膀胱癌盛行率上升、诊断工具不断改进以及加护治疗需求不断增长，预计北美将在预测期内占据最大的市场占有率。人口老化和吸烟增多是导致癌症发生率上升的重要变数。此外，非侵入性诊断技术和免疫疗法的进步、医疗保健和研究资金的增加正在推动该地区的市场扩张。

复合年增长率最高的地区：

由于癌症发病率上升、医疗保健意识增强、诊断技术的进步以及对标靶治疗的需求不断增加，预计亚太地区将在预测期内实现最高的复合年增长率。该地区医疗保健基础设施的扩建和微创手术的采用也促进了市场的成长。此外，对新型生物标记和免疫疗法的持续研究，以及获得先进治疗的机会的改善，也推动了亚太地区采用创新的膀胱癌诊断和治疗方案。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业进行基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球膀胱癌治疗与诊断市场（依癌症类型）

  • 膀胱移行细胞癌
  • 鳞状细胞膀胱癌
  • 其他类型癌症

6. 全球膀胱癌治疗与诊断市场（依治疗方法）

  • 化疗
  • 免疫疗法
  • 标靶治疗
  • 放射线治疗
  • 外科手术
  • 其他疗法

7. 全球膀胱癌治疗与诊断市场（依诊断）

  • 膀胱镜检查
  • 膀胱超音波
  • 尿液检查
  • 切片检查
  • 血液检查
  • 其他诊断

8. 全球膀胱癌治疗与诊断市场（依治疗阶段）

  • 膀胱癌早期
  • 晚期膀胱癌

9. 全球膀胱癌治疗和诊断市场（按最终用户）

  • 医院
  • 癌症研究所
  • 诊断实验室
  • 门诊手术中心
  • 其他最终用户

第 10 章。

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Hoffmann-La Roche AG
  • Johnson & Johnson
  • Kaiser Permanente
  • Merck & Co., Inc.
  • Novartis International AG
  • Pacific Edge Limited
  • Pfizer Inc.
  • Sanofi SA
Product Code: SMRC28393

According to Stratistics MRC, the Global Bladder Cancer Therapeutics and Diagnostics Market is accounted for $471.5 million in 2024 and is expected to reach $786.4 million by 2030 growing at a CAGR of 8.9% during the forecast period. Bladder cancer therapies and diagnostics are the medical treatments and technologies used to manage and identify bladder cancer. Therapeutics includes a range of treatments such as surgery, chemotherapy, immunotherapy, radiation therapy, and targeted therapy, aimed at killing cancer cells or preventing their growth. Diagnostics involve various tests and procedures, such as urine tests, cystoscopy, imaging (e.g., CT scans, ultrasounds), and biopsy, to detect and stage the cancer. Early detection and advanced treatments are crucial for improving survival rates, and ongoing research in personalized medicine is enhancing the effectiveness of both therapeutic and diagnostic approaches.

According to the American Cancer Society, in 2022, there are around 81,180 new cases of bladder cancer 61,700 in men and 19,480 in women in the United States.

Market Dynamics:

Driver:

Rising Incidence of Bladder Cancer

The rising incidence of bladder cancer is extensively driving the bladder cancer therapeutics and diagnostics market. As more individuals are diagnosed, there is increased demand for advanced diagnostic tools, such as imaging and biomarker testing, and innovative treatment options, including targeted therapies, immunotherapies, and chemotherapy. This growing need for early detection and personalized treatments is propelling market growth, with healthcare providers and pharmaceutical companies focusing on developing novel therapies and diagnostic solutions to address the rising prevalence of bladder cancer.

Restraint:

High Treatment Costs

The high expense of bladder cancer diagnostics and treatments is a significant barrier to market expansion, especially in low- and middle-income nations. Patient access and affordability are restricted by the high cost of modern medicines, such as immunotherapies and targeted treatments. This problem is made worse by gaps in insurance coverage and out-of-pocket costs, which obstruct prompt diagnosis and efficient treatment, delaying patient results and impeding wider market adoption.

Opportunity:

Early Detection Technologies

Early detection technologies are significantly impacting the bladder cancer therapeutics and diagnostics market by enabling earlier diagnosis, improving treatment outcomes, and reducing mortality rates. Technologies such as liquid biopsy, imaging advancements, and biomarker testing allow for the identification of cancer at its initial stages, leading to personalized treatment plans. This enhances the efficiency of therapies, minimizes side effects, and reduces healthcare costs. As a result, the market for bladder cancer diagnostics and treatments is expanding rapidly, driven by these innovations.

Threat:

Side Effects of Treatments

The adverse effects of bladder cancer therapies such as chemotherapy, immunotherapy, and radiation impede market growth by decreasing patient adherence and treatment efficacy. Fatigue, nausea, and immune-related problems are examples of adverse effects that might lower quality of life and cause therapy to be stopped or postponed. Patients and healthcare professionals become concerned about this, which slows the uptake of some treatments and hinders the market's overall growth for bladder cancer treatments and diagnostics.

Covid-19 Impact:

The COVID-19 pandemic disrupted the Bladder Cancer Therapeutics and Diagnostics Market by delaying elective surgeries, reducing patient visits, and limiting clinical trials. Diagnostic testing and treatment availability were impacted, leading to treatment postponements. However, the growing focus on cancer care post-pandemic, along with accelerated adoption of telemedicine and remote diagnostics has supported market recovery, driving demand for innovative therapies and diagnostic solutions in the long term.

The cystoscopy segment is expected to be the largest during the forecast period

The cystoscopy segment is expected to be the largest during the forecast period as it allows for direct visualization of the bladder lining, aiding in the identification of tumors or abnormalities. This diagnostic tool supports biopsy procedures, contributing to more precise treatment planning. As bladder cancer cases increase globally, cystoscopy's role in early-stage diagnosis and subsequent therapeutic interventions is driving growth in both the diagnostics and therapeutics sectors.

The radiotherapy segment is expected to have the highest CAGR during the forecast period

The radiotherapy segment is expected to have the highest CAGR during the forecast period because it is often combined with surgery or chemotherapy to improve survival rates. Advances in radiotherapy techniques, such as image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT), have enhanced precision, reducing side effects. These innovations are driving the market, along with the increasing demand for advanced diagnostic tools to monitor treatment efficacy and detect recurrence.

Region with largest share:

North America is anticipated to hold the largest market share during the forecast period because of the rising prevalence of bladder cancer, improvements in diagnostic tools, and the expanding need for focused treatments. The aging of the population and the increase in smoking are important variables that lead to increased cancer rates. Furthermore, advances in non-invasive diagnostic technologies and immunotherapies, as well as increased healthcare access and research funding, are driving market expansion in the area.

Region with highest CAGR:

Asia Pacific is anticipated to witness the highest CAGR over the forecast period owing to rising cancer incidences, increasing healthcare awareness, advancements in diagnostic technologies, and growing demand for targeted therapies. The region's expanding healthcare infrastructure and the adoption of minimally invasive procedures also contribute to market growth. Additionally, ongoing research into novel biomarkers and immunotherapies, along with enhanced access to advanced treatments, are boosting the adoption of innovative diagnostic and therapeutic solutions for bladder cancer in Asia-Pacific.

Key players in the market

Some of the key players in Bladder Cancer Therapeutics and Diagnostics market include Abbott Laboratories, AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., GlaxoSmithKline PLC, Hoffmann-La Roche AG, Johnson & Johnson, Kaiser Permanente, Merck & Co., Inc., Novartis International AG, Pacific Edge Limited, Pfizer Inc. and Sanofi S.A.

Key Developments:

In September 2024, iCardio.ai announced collaboration with Abbott to develop AI applications for the medtech giant's imaging technologies.

In August 2024, Abbott announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading1 FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.

In August 2024, The American Diabetes Association and Abbott recently announced a collaboration to better understand the nutritional needs of people living with diabetes, obesity, and metabolic dysfunction and how nutrition formulas can support those needs and overall health.

Cancer Types Covered:

  • Transitional Cell Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Other Cancer Types

Therapeutics Covered:

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiotherapy
  • Surgical Procedures
  • Other Therapeutics

Diagnostics Covered:

  • Cystoscopy
  • Bladder Ultrasound
  • Urinalysis
  • Biopsy
  • Blood Tests
  • Other Diagnostics

Treatment Stages Covered:

  • Early-Stage Bladder Cancer
  • Advanced-Stage Bladder Cancer

End Users Covered:

  • Hospitals
  • Cancer Research Institutes
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bladder Cancer Therapeutics and Diagnostics Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Transitional Cell Bladder Cancer
  • 5.3 Squamous Cell Bladder Cancer
  • 5.4 Other Cancer Types

6 Global Bladder Cancer Therapeutics and Diagnostics Market, By Therapeutics

  • 6.1 Introduction
  • 6.2 Chemotherapy
  • 6.3 Immunotherapy
  • 6.4 Targeted Therapy
  • 6.5 Radiotherapy
  • 6.6 Surgical Procedures
  • 6.7 Other Therapeutics

7 Global Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostics

  • 7.1 Introduction
  • 7.2 Cystoscopy
  • 7.3 Bladder Ultrasound
  • 7.4 Urinalysis
  • 7.5 Biopsy
  • 7.6 Blood Tests
  • 7.7 Other Diagnostics

8 Global Bladder Cancer Therapeutics and Diagnostics Market, By Treatment Stage

  • 8.1 Introduction
  • 8.2 Early-Stage Bladder Cancer
  • 8.3 Advanced-Stage Bladder Cancer

9 Global Bladder Cancer Therapeutics and Diagnostics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Cancer Research Institutes
  • 9.4 Diagnostic Laboratories
  • 9.5 Ambulatory Surgical Centers
  • 9.6 Other End Users

10 Global Bladder Cancer Therapeutics and Diagnostics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 AstraZeneca PLC
  • 12.3 Bristol-Myers Squibb Company
  • 12.4 Celgene Corporation
  • 12.5 Eli Lilly and Company
  • 12.6 Endo Pharmaceuticals Inc.
  • 12.7 F. Hoffmann-La Roche Ltd
  • 12.8 Genentech, Inc.
  • 12.9 GlaxoSmithKline PLC
  • 12.10 Hoffmann-La Roche AG
  • 12.11 Johnson & Johnson
  • 12.12 Kaiser Permanente
  • 12.13 Merck & Co., Inc.
  • 12.14 Novartis International AG
  • 12.15 Pacific Edge Limited
  • 12.16 Pfizer Inc.
  • 12.17 Sanofi S.A.

List of Tables

  • Table 1 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Cancer Type (2022-2030) ($MN)
  • Table 3 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Transitional Cell Bladder Cancer (2022-2030) ($MN)
  • Table 4 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Squamous Cell Bladder Cancer (2022-2030) ($MN)
  • Table 5 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other Cancer Types (2022-2030) ($MN)
  • Table 6 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 7 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 8 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 9 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Targeted Therapy (2022-2030) ($MN)
  • Table 10 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Radiotherapy (2022-2030) ($MN)
  • Table 11 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Surgical Procedures (2022-2030) ($MN)
  • Table 12 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other Therapeutics (2022-2030) ($MN)
  • Table 13 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 14 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Cystoscopy (2022-2030) ($MN)
  • Table 15 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Bladder Ultrasound (2022-2030) ($MN)
  • Table 16 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Urinalysis (2022-2030) ($MN)
  • Table 17 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 18 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 19 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other Diagnostics (2022-2030) ($MN)
  • Table 20 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Treatment Stage (2022-2030) ($MN)
  • Table 21 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Early-Stage Bladder Cancer (2022-2030) ($MN)
  • Table 22 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Advanced-Stage Bladder Cancer (2022-2030) ($MN)
  • Table 23 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By End User (2022-2030) ($MN)
  • Table 24 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 25 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Cancer Research Institutes (2022-2030) ($MN)
  • Table 26 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 27 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
  • Table 28 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.